Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Klotho Neurosciences's annualized net income for the quarter that ended in Sep. 2025 was $-11.58 Mil. Klotho Neurosciences's average shareholder tangible equity for the quarter that ended in Sep. 2025 was $7.99 Mil. Therefore, Klotho Neurosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Sep. 2025 was -145.01%.
The historical rank and industry rank for Klotho Neurosciences's Return-on-Tangible-Equity or its related term are showing as below:
KLTO'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -457.01 Med: -383.74 Max: -383.74
Current: -457.01
During the past 4 years, Klotho Neurosciences's highest Return-on-Tangible-Equity was -383.74%. The lowest was -457.01%. And the median was -383.74%.
KLTO's Return-on-Tangible-Equity is not ranked
in the Biotechnology industry.
Industry Median: -42.4
vs KLTO: -457.01
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Klotho Neurosciences Return-on-Tangible-Equity Related Terms
Klotho Neurosciences Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Klotho Neurosciences's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KLTO vs KTTA, JUNS, ZEOX: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Klotho Neurosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Klotho Neurosciences Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Klotho Neurosciences's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Klotho Neurosciences's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Sep. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -145.01% mean?
Klotho Neurosciences (KLTO) has a Return-on-Tangible-Equity of -145.01% as of Sep. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Klotho Neurosciences and its competitors.
Is Klotho Neurosciences' Return-on-Tangible-Equity too high?
Klotho Neurosciences' current Return-on-Tangible-Equity is -145.01%. Overall, Klotho Neurosciences has a GF Score™ of 22/100, reflecting its overall financial health beyond just this single metric.
How does Klotho Neurosciences' Return-on-Tangible-Equity compare to KTTA and JUNS?
Klotho Neurosciences' Return-on-Tangible-Equity of -145.01% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Klotho Neurosciences and its competitors. Klotho Neurosciences's current Return-on-Tangible-Equity is -145.01%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Klotho Neurosciences stock overvalued right now?
Klotho Neurosciences (KLTO) has a current Return-on-Tangible-Equity of -145.01%. The current Return-on-Tangible-Equity is -145.01%. Klotho Neurosciences' overall GF Score™ is 22/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Klotho Neurosciences (KLTO), the current Return-on-Tangible-Equity is -145.01% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.
22GF Score
Get the complete analysis for KLTO
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLTO has been successfully added to your 
